Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Atomoxetine Hydrochloride Versus Placebo in Taiwanese Children and Adolescents With ADHD

This study has been completed.
Information provided by:
Eli Lilly and Company Identifier:
First received: June 11, 2007
Last updated: NA
Last verified: June 2007
History: No changes posted

June 11, 2007
June 11, 2007
February 2004
Not Provided
Test the hypothesis that atomoxetine administered as a single-daily dose provides superior efficacy compared with placebo in Taiwanese children and adolescents with ADHD
Same as current
No Changes Posted
  • Compare the improvement in symptoms associated with ADHD in children and adolescents achieved by once-daily dosing of atomoxetine or placebo
  • Compare the reduction in school-related symptoms between atomoxetine and placebo
  • Assess the safety and tolerability of once-daily dosing of atomoxetine
Same as current
Not Provided
Not Provided
Atomoxetine Hydrochloride Versus Placebo in Taiwanese Children and Adolescents With ADHD
Efficacy, Tolerability, and Safety of Once-Daily Atomoxetine Hydrochloride Versus Placebo in Taiwanese Children and Adolescents With Attention-Deficit/Hyperactivity Disorder
The purpose of this protocol is to investigate the acute treatment efficacy, safety, and tolerability of atomoxetine on a once-daily dosing strategy in Taiwanese children and adolescents with ADHD.
Not Provided
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Attention Deficit Hyperactivity Disorder
  • Drug: Atomoxetine Hydrochloride
  • Drug: Placebo
Not Provided
Bangs ME, Wietecha LA, Wang S, Buchanan AS, Kelsey DK. Meta-analysis of suicide-related behavior or ideation in child, adolescent, and adult patients treated with atomoxetine. J Child Adolesc Psychopharmacol. 2014 Oct;24(8):426-34. doi: 10.1089/cap.2014.0005. Epub 2014 Jul 14.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
November 2004
Not Provided

Inclusion Criteria:

  • Subject must have ADHD that meet DSM-IV disease diagnostic criteria as well as severity criteria
  • Subjects must be aged 6 to 16 years
  • Subjects must not have taken any medication used to treat ADHD or they must have completed the washout procedures
  • Subjects must be able to swallow capsules
  • Subjects must be of normal intelligence in the judgment of the investigator. Normal intelligence is defined as being without evidence of significant general intellectual deficit and expected to achieve a score of 80 or more if formal IQ testing were administered.

Exclusion Criteria:

  • Weigh less than 20 kg or more than 60 kg at study entry
  • Have a history of Bipolar I or II disorder, psychosis, or pervasive developmental disorder
  • Meet DSM-IV criteria for an anxiety disorder as assessed by the investigator
  • Have a history of any seizure disorder (other than febrile seizures) or prior ECG abnormalities related to epilepsy, or subjects who have taken (or are currently taking) anticonvulsants for seizure control
  • Subjects who have a history of severe allergies to more than 1 class of medications or multiple adverse drug reactions.
6 Years to 16 Years   (Child)
Contact information is only displayed when the study is recruiting subjects
8160, B4Z-TW-S010
Not Provided
Not Provided
Not Provided
Not Provided
Eli Lilly and Company
Not Provided
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company
Eli Lilly and Company
June 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP